Pre-erythrocytic Activity of M5717 in Monotherapy and Combination in Preclinical Plasmodium Infection Models.
Sign Up to like & getrecommendations! Published in 2022 at "ACS infectious diseases"
DOI: 10.1021/acsinfecdis.1c00640
Abstract: Combination therapies have emerged to mitigate Plasmodium drug resistance, which has hampered the fight against malaria. M5717 is a potent multistage antiplasmodial drug under clinical development, which inhibits parasite protein synthesis. The combination of M5717… read more here.
Keywords: infection; plasmodium infection; activity m5717; combination ... See more keywords